Biomarker-directed Treatment of Acute Exacerbations of Asthma

20 Nov 2026 11:15 11:30
Anthony Yii Speaker Singapore
Acute asthma exacerbations are conventionally treated with a standard course of systemic corticosteroids, regardless of the underlying inflammatory phenotype. However, increasing evidence suggests that exacerbations are biologically heterogeneous, with differences in corticosteroid responsiveness between type 2-high and type 2-low inflammation. Repeated corticosteroid exposure also contributes to substantial long-term morbidity and healthcare costs. This presentation examines the rationale and emerging evidence for biomarker-directed treatment of acute asthma exacerbations. Transcriptomic studies demonstrate differential corticosteroid effects across inflammatory pathways, while clinical studies suggest that physiological responses may vary according to inflammatory phenotype. Findings from a randomized controlled trial evaluating blood eosinophil-guided corticosteroid duration in hospitalized asthma exacerbations will be presented, alongside emerging evidence for biologic therapies during acute exacerbations. Together, these findings support a shift towards more individualized exacerbation management, with the potential to reduce unnecessary corticosteroid exposure while maintaining clinical effectiveness. Larger confirmatory trials are needed before widespread implementation.